![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Insulin X10 revisited: a super-mitogenic insulin analogue
The molecular safety of insulin analogues has received a great deal of attention over the last year. In particular, attention has been directed to the mitogenic properties of insulin analogues as compared with...
-
Article
No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis
Recent epidemiological studies suggest that treatment with insulin glargine (A21Gly,B31Arg,B32Arg human insulin) may promote cancer growth. The present meta-analysis was performed to assess the risk of cancer ...
-
Article
40th EASD Annual Meeting of the European Association for the Study of Diabetes
-
Article
Improved postprandial glycaemic controls with insulin Aspart in type 2 diabetic patients treated with insulin
The effect on postprandial blood glucose control of an immediately pre-meal injection of the rapid acting insulin analogue Aspart (IAsp) was compared with that of human insulin Actrapid injected immediately o...
-
Article
35th Annual Meeting of the European Association for the Study of Diabetes
-
Article
Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 (non-insulin-dependent) diabetic patients
The prevalence of micro- and macroalbuminuria was determined in Type 2 (non-insulin-dependent) diabetic patients, less than 76 years of age, attending a diabetic clinic during 1987. All eligible patients (n=557) ...
-
Article
Plasma adrenaline kinetics in Type 1 (insulin-dependent) diabetic patients with and without autonomie neuropathy
Plasma adrenaline kinetics (clearance, extraction across the forearm, initial plasma disappearance rate, mean sojourn time, volume of distribution) were studied in sixteen Type 1 (insulin-dependent) diabetic p...
-
Article
Plasma concentrations of pituitary and peripheral hormones during ranitidine treatment for two years in men with duodenal ulcer
The effects of treatment for 2 years with the histamine H2-receptor antagonist ranitidine (100 or 200 mg b.d. for 6 weeks followed by 100 or 200 mg daily) on plasma concentrations of pituitary and peripheral horm...